At a glance
- Originator Pharmacia Corporation
- Class Antirheumatics
- Mechanism of Action Cyclo-oxygenase 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Rheumatic disorders
Most Recent Events
- 25 Mar 1999 No-Development-Reported for Rheumatic disorders in USA (Unknown route)
- 19 Dec 1996 Phase-I clinical trials for Rheumatic disorders in USA (Unknown route)
- 24 Jun 1996 Preclinical development for Rheumatic disorders in USA (Unknown route)